P3781
Anaplastic large cell lymphoma, ALK-negativeFolotyn (pralatrexate injection) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma: U.S. Food and Drug Administration drug approval summary.Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyEvaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma.Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study.Single agent and combination studies of pralatrexate and molecular correlates of sensitivity.Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphomaPML-IRIS in a patient treated with brentuximabPrimary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.Peripheral T-cell lymphoma--not otherwise specified.New drug therapies in peripheral T-cell lymphoma.Therapeutic advances in cutaneous T-cell lymphomaTargeted molecular therapy in peripheral T-cell lymphomas.Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.Clinical development of new formulations of cytotoxics in solid tumors.Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance.Pralatrexate (Folotyn).Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma.Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.Peripheral T-cell lymphomas: diagnosis and treatment options. Proceedings from a live roundtable, August 17, 2011, Kauai, Hawaii.Pralatrexate for lymphomaPralatrexate (Folotyn) for peripheral T-cell lymphomaLack of expression of MTAP in uncommon T-cell lymphomas
P921
Q26994695-243ED44D-E0C2-4223-890D-3F96AFAE40F8Q33391588-94DE10E6-6517-4A3F-B786-0CBA4B1F4C75Q33393701-2351AA74-A25A-4D35-B1C2-E4CFEFECC7C1Q33396068-43377F0B-5FD7-4487-A4EC-2336A72FA8E9Q33400117-44A1D1A4-5017-4768-B2F6-88FB49477970Q33400977-82383C3C-5A90-4E6C-8945-F4B5889D9972Q34543815-39D86BFD-BBA6-47EC-B096-6BC3B8D07B0FQ36283958-2E086EF7-A8E5-455E-976A-A4D4D46ABF7AQ36439197-04F9AB0A-CEE9-4E2A-BD99-B96D28A85A54Q37776476-6BA136E9-088B-453C-B049-054C1046C1CAQ37779392-90857F49-7491-4417-B742-CB92878A05B7Q37854715-CA9AE887-7C8A-401F-800C-BDFDB9F3B784Q37876869-6555AD95-10F2-4315-819D-104CCC64B5FDQ37937044-1C96896D-4568-423C-835B-4146D16CB2FAQ37940292-7B98B389-B655-46A2-8A82-F0AEBC78C711Q37985477-640237FA-F10D-49C5-A924-E234735F324FQ37998019-16281E0A-E778-4554-AB33-147669BC8A85Q38037835-DE7E85E0-5261-4171-9D8E-0516D905C26BQ38046218-74A8FEEF-89C9-45CF-B34F-230F34A01FF2Q38944954-03F26EB6-917A-4946-9EAF-D23ADF4E1A63Q39624766-AF4B5912-313C-4439-B295-38E7A15640CEQ39717669-057B2BB2-CB83-4675-BD32-1FBC7A1C4465Q44600477-47A5540F-8527-47E8-BECA-12D131045040Q64085686-20551244-BCE0-421B-9562-0BEE18ACC686Q84560987-5BDCDB6F-71C7-4E5F-960B-D1183B3B36C8Q87414140-D7EAD172-BF32-47DB-9E22-501E5A105325
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische stof
@nl
name
Pralatreksat
@sh
Pralatreksat
@sr
Pralatrexate
@vi
Pralatrexát
@hu
pralatreksat
@pl
pralatrexate
@en
پرالاترکسات
@azb
پرالاترکسات
@fa
type
label
Pralatreksat
@sh
Pralatreksat
@sr
Pralatrexate
@vi
Pralatrexát
@hu
pralatreksat
@pl
pralatrexate
@en
پرالاترکسات
@azb
پرالاترکسات
@fa
altLabel
(2S)-2-((4-((1RS)-1-((2,4-Diam ...... enzoyl)amino)pentanedioic acid
@en
(2S)-2-((4-((1RS)-1-((2,4-diam ...... enzoyl)amino)pentanedioic acid
@en
(2S)-2-({4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl}amino)pentanedioic acid
@en
10-Propargyl-10-deazaaminopterin
@en
Folotyn®
@en
HSDB 7786
@en
N-(4-(1-((2,4-Diamino-6-pteridinyl)methyl)-3-butynyl)benzoyl)-L-glutamic acid
@en
PDX
@en
Pralatrexate
@en
Pralatrexato
@en
prefLabel
Pralatreksat
@sh
Pralatreksat
@sr
Pralatrexate
@vi
Pralatrexát
@hu
pralatreksat
@pl
pralatrexate
@en
پرالاترکسات
@azb
پرالاترکسات
@fa
P31
P592
P6366
P661
P662
P665
P683
P1579
P2017
C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O
P2067
477.176067
P2115
N0000180303